Home About Us Services & Capabilities Sustainability Careers Investors News & Resources Contact Us 中文 / CN Deutsch / DE 日本語 / JP 한글 / KR About Us Company Leadership Locations & Facilities Company Vision & Mission CRDMO⁺ PROUD Culture History &…
About Us
Company
Services & Capabilities
-
Production Systems
-
Capabilities
-
Quality
-
Featured Platforms
Production Systems
-
Mammalian
$Our expertise spans discovery, development, and cGMP manufacture of biologics from mammalian cell culture. Leveraging 6 discovery platforms, a top-tier CMC development team, and an extensive supply chain, we deliver seamless programs for all your biologics drug development needs.
-
Microbial
$Comprehensive CMC development and cGMP manufacturing microbial fermentation platform. E. coli and yeast-based expression systems for the production of plasmid DNA and recombinant proteins.
Mammalian$Our expertise spans discovery, development, and cGMP manufacture of biologics from mammalian cell culture. Leveraging 6 discovery platforms, a top-tier CMC development team, and an extensive supply chain, we deliver seamless programs for all your biologics drug development needs.
Mammalian-Derived Product Services$A true single-source provider from concept to commercialization for biologics produced from mammalian cell culture.
Mammalian-Derived Product Services
A true single-source provider from concept to commercialization for biologics produced from mammalian cell culture.
Learn more
Monoclonal Antibodies$Discover information about the various drug development services we provide for this product type
Monoclonal Antibodies
Discover information about the various drug development services we provide for this product type
Learn more
Bispecific & Multispecific Antibodies$Discover information about the various drug development services we provide for this product type
Bispecific & Multispecific Antibodies
Discover information about the various drug development services we provide for this product type
Learn more
Fc-Fusion Proteins$Discover information about the various drug development services we provide for this product type
Fc-Fusion Proteins
Discover information about the various drug development services we provide for this product type
Learn more
Antibody Fragments$Discover information about the various drug development services we provide for this product type
Antibody Fragments
Discover information about the various drug development services we provide for this product type
Learn more
Recombinant Proteins / Enzymes / Cytokines$Discover information about the various drug development services we provide for this product type
Recombinant Proteins / Enzymes / Cytokines
Discover information about the various drug development services we provide for this product type
Learn more
Antibody Drug Conjugates (ADCs)$Discover information about the various drug development services we provide for this product type
Antibody Drug Conjugates (ADCs)
Discover information about the various drug development services we provide for this product type
Learn more
Virus-Like Particles (VLPs)$Discover information about the various drug development services we provide for this product type
Virus-Like Particles (VLPs)
Discover information about the various drug development services we provide for this product type
Learn more
Microbial$Comprehensive CMC development and cGMP manufacturing microbial fermentation platform. E. coli and yeast-based expression systems for the production of plasmid DNA and recombinant proteins.
Microbial Product Class$High quality, expert services for biologics produced from microbial fermentation.
Microbial Product Class
High quality, expert services for biologics produced from microbial fermentation.
Learn more
Antibody Fragments$Discover information about the various drug development services we provide for this product type
Antibody Fragments
Discover information about the various drug development services we provide for this product type
Learn more
Enzymes$Discover information about the various drug development services we provide for this product type
Enzymes
Discover information about the various drug development services we provide for this product type
Learn more
Cytokines$Discover information about the various drug development services we provide for this product type
Cytokines
Discover information about the various drug development services we provide for this product type
Learn more
Virus-Like Particles (VLPs)$Discover information about the various drug development services we provide for this product type
Virus-Like Particles (VLPs)
Discover information about the various drug development services we provide for this product type
Learn more
Capabilities
-
Research
$Integrated Discovery Platform From Concept to IND
-
Development
$Utilizing one of the world’s largest and most experienced development teams, we have the resources, technologies and expertise to drive your program toward IND and BLA in the most efficient and cost-effective manner.
-
Manufacturing
$Multiple state-of-the-art, premier quality cGMP clinical- and commercial-scale drug substance (DS) and drug product (DP) facilities across four countries for the production of a wide array of biologics from both mammalian and microbial expression systems.
-
Testing
$We provide extensive expertise for in-process, characterization, release and stability method development and testing either in support of our integrated biologics development platforms or as standalone projects. Our wide-range of analytical and biosafety testing Centers of Excellence and regulatory agency-approved quality control (QC) laboratories are the backbone of every service we provide our clients.
Research$Integrated Discovery Platform From Concept to IND
-
Antibody Discovery Services
$We offer customized antibody discovery platforms for monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), multispecific antibodies (msAbs), immunocytokines, and other therapeutic modalities, to accelerate biology-driven lead identification.
-
Protein Production & Engineering Services
$At WuXi Biologics, we specialize in the production and engineering of monoclonal, bispecific, and multi-specific antibodies, fusion-proteins, cytokines, enzymes, and novel biologics. With industry-leading expertise, state-of-the-art facilities and proprietary technologies, we offer our customers high-quality protein engineering and production services for research use.
-
Protein Characterization Services
$At WuXi Biologics, we provide comprehensive protein characterization testing to help you triage and optimize your lead candidates. Our integrated protein characterization and analytics platform includes purity/impurity testing, structure characterization assessment, including MS-based protein ID and post-translational modification analysis, and function testing (e.g., SPR/ELISA/cell-based activity assays).
-
In Vitro Assays Services
$Leveraging advanced in vitro assay technologies such as cellular, biochemical, molecular, immune, and Fc effector function assays, we deliver reproducible, high-quality results with data interpretation to support biologics discovery and development.
-
In Vivo Pharmacology Services
$Our multi-species in vivo pharmacology services provide science-driven solutions for preclinical studies, including pharmacokinetic (PK) and pharmacodynamic (PD) evaluations, efficacy models, toxicology studies, and immunohistology.
Antibody Discovery Services$We offer customized antibody discovery platforms for monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), multispecific antibodies (msAbs), immunocytokines, and other therapeutic modalities, to accelerate biology-driven lead identification.
Antibody Discovery Services
We offer customized antibody discovery platforms for monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), multispecific antibodies (msAbs), immunocytokines, and other therapeutic modalities, to accelerate biology-driven lead identification.
Learn more
Protein Production & Engineering Services$At WuXi Biologics, we specialize in the production and engineering of monoclonal, bispecific, and multi-specific antibodies, fusion-proteins, cytokines, enzymes, and novel biologics. With industry-leading expertise, state-of-the-art facilities and proprietary technologies, we offer our customers high-quality protein engineering and production services for research use.
Protein Production & Engineering Services
At WuXi Biologics, we specialize in the production and engineering of monoclonal, bispecific, and multi-specific antibodies, fusion-proteins, cytokines, enzymes, and novel biologics. With industry-leading expertise, state-of-the-art facilities and proprietary technologies, we offer our customers high-quality protein engineering and production services for research use.
Learn more
Protein Characterization Services$At WuXi Biologics, we provide comprehensive protein characterization testing to help you triage and optimize your lead candidates. Our integrated protein characterization and analytics platform includes purity/impurity testing, structure characterization assessment, including MS-based protein ID and post-translational modification analysis, and function testing (e.g., SPR/ELISA/cell-based activity assays).
Protein Characterization Services
At WuXi Biologics, we provide comprehensive protein characterization testing to help you triage and optimize your lead candidates. Our integrated protein characterization and analytics platform includes purity/impurity testing, structure characterization assessment, including MS-based protein ID and post-translational modification analysis, and function testing (e.g., SPR/ELISA/cell-based activity assays).
Learn more
In Vitro Assays Services$Leveraging advanced in vitro assay technologies such as cellular, biochemical, molecular, immune, and Fc effector function assays, we deliver reproducible, high-quality results with data interpretation to support biologics discovery and development.
In Vitro Assays Services
Leveraging advanced in vitro assay technologies such as cellular, biochemical, molecular, immune, and Fc effector function assays, we deliver reproducible, high-quality results with data interpretation to support biologics discovery and development.
Learn more
In Vivo Pharmacology Services$Our multi-species in vivo pharmacology services provide science-driven solutions for preclinical studies, including pharmacokinetic (PK) and pharmacodynamic (PD) evaluations, efficacy models, toxicology studies, and immunohistology.
In Vivo Pharmacology Services
Our multi-species in vivo pharmacology services provide science-driven solutions for preclinical studies, including pharmacokinetic (PK) and pharmacodynamic (PD) evaluations, efficacy models, toxicology studies, and immunohistology.
Learn more
Development$Utilizing one of the world’s largest and most experienced development teams, we have the resources, technologies and expertise to drive your program toward IND and BLA in the most efficient and cost-effective manner.
-
Mammalian Cell Line Development
$Generate stable CHO and HEK293 cell lines at industry-leading speed and global scale.
-
Microbial Strain Development
$Generate microbial strains and viral production systems from a variety of modalities.
-
Analytical Sciences
$Our extensive analytical testing services offer top-tier expertise in method development for in-process, release, and stability assays, and support of cell line, process, and formulation development activities, product characterization, developability assessments and other key IND- and BLA-enabling studies.
-
Process Development & Scale Up
$Multiple upstream and downstream PD labs facilitate the establishment and scale-up of fed-batch, intensified fed-batch, and continuous manufacturing approaches for diverse biotherapeutic modalities in both early and late-stage development.
-
Late-Stage Development
$Late-stage development scales processes for commercialization, culminating in biologic characterization, characterization, and validation.
-
Process Characterization
$Process characterization supports drug substance production within a data-driven framework that streamlines PPQ and meets global compliance requirements.
-
Formulation & Drug Product Development
$We provide advanced drug product development services spanning biologics, vaccines, and small molecules, with expertise in formulating clinical and commercial products in liquid, frozen, and lyophilized forms, compatible with various container closure systems such as vials, prefilled syringes, and other combination product types.
-
Cell Banking & Characterization
$Offering in-house, one-stop cell banking and cell line characterization services, compliant with global GMP regulations and ICH guidelines, we operate over 20 cGMP cell banking suites ensuring capacity availability and timely execution of this critical CMC development activity.
-
Viral Clearance
$Our extensive experience and expertise, along with EMA, ISO (CNAS), and CMA-certified laboratories, and exceptional track record for IND- and BLA-enabling viral clearance study acceptance by global regulatory agencies, form the cornerstones for this pivotal aspect of any CMC development program.
-
Regulatory Support
$Our experienced regulatory affairs team supports drug filing and registration with over 370 INDs/CTAs, 20+ BLAs/MAAs/NDAs/EUAs, and 150 Module 3 CMC packages since 2015.
Mammalian Cell Line Development$Generate stable CHO and HEK293 cell lines at industry-leading speed and global scale.
Mammalian Cell Line Development
Generate stable CHO and HEK293 cell lines at industry-leading speed and global scale.
Learn more
Microbial Strain Development$Generate microbial strains and viral production systems from a variety of modalities.
Microbial Strain Development
Generate microbial strains and viral production systems from a variety of modalities.
Learn more
Analytical Sciences$Our extensive analytical testing services offer top-tier expertise in method development for in-process, release, and stability assays, and support of cell line, process, and formulation development activities, product characterization, developability assessments and other key IND- and BLA-enabling studies.
Analytical Sciences
Our extensive analytical testing services offer top-tier expertise in method development for in-process, release, and stability assays, and support of cell line, process, and formulation development activities, product characterization, developability assessments and other key IND- and BLA-enabling studies.
Learn more
Process Development & Scale Up$Multiple upstream and downstream PD labs facilitate the establishment and scale-up of fed-batch, intensified fed-batch, and continuous manufacturing approaches for diverse biotherapeutic modalities in both early and late-stage development.
Process Development & Scale Up
Multiple upstream and downstream PD labs facilitate the establishment and scale-up of fed-batch, intensified fed-batch, and continuous manufacturing approaches for diverse biotherapeutic modalities in both early and late-stage development.
Learn more
Late-Stage Development$Late-stage development scales processes for commercialization, culminating in biologic characterization, characterization, and validation.
Late-Stage Development
Late-stage development scales processes for commercialization, culminating in biologic characterization, characterization, and validation.
Learn more
Process Characterization$Process characterization supports drug substance production within a data-driven framework that streamlines PPQ and meets global compliance requirements.
Process Characterization
Process characterization supports drug substance production within a data-driven framework that streamlines PPQ and meets global compliance requirements.
Learn more
Formulation & Drug Product Development$We provide advanced drug product development services spanning biologics, vaccines, and small molecules, with expertise in formulating clinical and commercial products in liquid, frozen, and lyophilized forms, compatible with various container closure systems such as vials, prefilled syringes, and other combination product types.
Formulation & Drug Product Development
We provide advanced drug product development services spanning biologics, vaccines, and small molecules, with expertise in formulating clinical and commercial products in liquid, frozen, and lyophilized forms, compatible with various container closure systems such as vials, prefilled syringes, and other combination product types.
Learn more
Cell Banking & Characterization$Offering in-house, one-stop cell banking and cell line characterization services, compliant with global GMP regulations and ICH guidelines, we operate over 20 cGMP cell banking suites ensuring capacity availability and timely execution of this critical CMC development activity.
Cell Banking & Characterization
Offering in-house, one-stop cell banking and cell line characterization services, compliant with global GMP regulations and ICH guidelines, we operate over 20 cGMP cell banking suites ensuring capacity availability and timely execution of this critical CMC development activity.
Learn more
Viral Clearance$Our extensive experience and expertise, along with EMA, ISO (CNAS), and CMA-certified laboratories, and exceptional track record for IND- and BLA-enabling viral clearance study acceptance by global regulatory agencies, form the cornerstones for this pivotal aspect of any CMC development program.
Viral Clearance
Our extensive experience and expertise, along with EMA, ISO (CNAS), and CMA-certified laboratories, and exceptional track record for IND- and BLA-enabling viral clearance study acceptance by global regulatory agencies, form the cornerstones for this pivotal aspect of any CMC development program.
Learn more
Regulatory Support$Our experienced regulatory affairs team supports drug filing and registration with over 370 INDs/CTAs, 20+ BLAs/MAAs/NDAs/EUAs, and 150 Module 3 CMC packages since 2015.
Regulatory Support
Our experienced regulatory affairs team supports drug filing and registration with over 370 INDs/CTAs, 20+ BLAs/MAAs/NDAs/EUAs, and 150 Module 3 CMC packages since 2015.
Learn more
Manufacturing$Multiple state-of-the-art, premier quality cGMP clinical- and commercial-scale drug substance (DS) and drug product (DP) facilities across four countries for the production of a wide array of biologics from both mammalian and microbial expression systems.
Clinical DS GMP Manufacturing$Operating multiple high-quality, state-of-the-art clinical-scale cGMP facilities for biologics drug substance (DS) production utilizing both mammalian and microbial expression systems.
Clinical DS GMP Manufacturing
Operating multiple high-quality, state-of-the-art clinical-scale cGMP facilities for biologics drug substance (DS) production utilizing both mammalian and microbial expression systems.
Learn more
Clinical DP GMP Manufacturing$Multiple, highly flexible clinical-scale drug product (DP) manufacturing facilities for the formulation, fill, labelling and packaging of biologics and parenterals under Current Good Manufacturing Practice (cGMP) conditions as defined by global regulatory agencies.
Clinical DP GMP Manufacturing
Multiple, highly flexible clinical-scale drug product (DP) manufacturing facilities for the formulation, fill, labelling and packaging of biologics and parenterals under Current Good Manufacturing Practice (cGMP) conditions as defined by global regulatory agencies.
Learn more
Commercial DS GMP Manufacturing$We provide a global dual source manufacturing network that employs multiple large-scale drug substance (DS) GMP manufacturing facilities for the production of biologics utilizing our world-class operations and regulatory agency-approved quality systems.
Commercial DS GMP Manufacturing
We provide a global dual source manufacturing network that employs multiple large-scale drug substance (DS) GMP manufacturing facilities for the production of biologics utilizing our world-class operations and regulatory agency-approved quality systems.
Learn more
Commercial DP GMP Manufacturing$Multiple large-scale drug product (DP) manufacturing facilities located across the globe for the high-quality formulation, fill, labelling and packaging of biologics, parenterals and placebo into a wide array of container closure systems.
Commercial DP GMP Manufacturing
Multiple large-scale drug product (DP) manufacturing facilities located across the globe for the high-quality formulation, fill, labelling and packaging of biologics, parenterals and placebo into a wide array of container closure systems.
Learn more
Testing$We provide extensive expertise for in-process, characterization, release and stability method development and testing either in support of our integrated biologics development platforms or as standalone projects. Our wide-range of analytical and biosafety testing Centers of Excellence and regulatory agency-approved quality control (QC) laboratories are the backbone of every service we provide our clients.
-
Biosafety Testing
$High quality, in-house and EMA, ISO (CNAS) and CMA certified biosafety testing facilities for adventitious agent screening of raw materials, cell lines and unprocessed bulk along with our extensive viral clearance capabilities is available to provide our clients with a single-source biosafety testing service offering.
-
Analytical Testing
$We offer an extensive array of assay development and analytical testing services, including bioassay development and forensic investigation analysis, along with other key characterization and IND and BLA-enabling studies throughout the various phases of drug development – all tailored for your unique product and project needs.
-
Bioassay Method Development Services
-
Product Characterization Service
-
Routine Analytical Testing Services
-
Centers of Excellence (CoE)
$Our CoEs support projects with specialized testing throughout the product lifecycle, expediting project timelines and ensuring analytical readiness for commercialization.
-
Global Quality Control (QC)
$Regulatory compliant, in-house, QC labs support all clinical and commercial GMP sites pre- and post-production, ensuring top-quality testing for products and oversight of other critical functions (e.g., environmental monitoring, cleaning validations, instrument life-cycle and sample/retain management and audits).
Biosafety Testing$High quality, in-house and EMA, ISO (CNAS) and CMA certified biosafety testing facilities for adventitious agent screening of raw materials, cell lines and unprocessed bulk along with our extensive viral clearance capabilities is available to provide our clients with a single-source biosafety testing service offering.
Biosafety Testing
High quality, in-house and EMA, ISO (CNAS) and CMA certified biosafety testing facilities for adventitious agent screening of raw materials, cell lines and unprocessed bulk along with our extensive viral clearance capabilities is available to provide our clients with a single-source biosafety testing service offering.
Learn more
Analytical Testing$We offer an extensive array of assay development and analytical testing services, including bioassay development and forensic investigation analysis, along with other key characterization and IND and BLA-enabling studies throughout the various phases of drug development – all tailored for your unique product and project needs.
Analytical Testing
We offer an extensive array of assay development and analytical testing services, including bioassay development and forensic investigation analysis, along with other key characterization and IND and BLA-enabling studies throughout the various phases of drug development – all tailored for your unique product and project needs.
Learn more
Centers of Excellence (CoE)$Our CoEs support projects with specialized testing throughout the product lifecycle, expediting project timelines and ensuring analytical readiness for commercialization.
Centers of Excellence (CoE)
Our CoEs support projects with specialized testing throughout the product lifecycle, expediting project timelines and ensuring analytical readiness for commercialization.
Learn more
Global Quality Control (QC)$Regulatory compliant, in-house, QC labs support all clinical and commercial GMP sites pre- and post-production, ensuring top-quality testing for products and oversight of other critical functions (e.g., environmental monitoring, cleaning validations, instrument life-cycle and sample/retain management and audits).
Global Quality Control (QC)
Regulatory compliant, in-house, QC labs support all clinical and commercial GMP sites pre- and post-production, ensuring top-quality testing for products and oversight of other critical functions (e.g., environmental monitoring, cleaning validations, instrument life-cycle and sample/retain management and audits).
Learn more
Quality
-
Quality & Regulatory
$We provide world-class quality systems, harmonized across our global manufacturing sites and approved by multiple global regulatory agencies, including the U.S. FDA, EMA, NMPA, PMDA, MFDS, HSA, ANVISA and Health Canada for the production and testing of a wide array of biologics.
Quality & Regulatory$We provide world-class quality systems, harmonized across our global manufacturing sites and approved by multiple global regulatory agencies, including the U.S. FDA, EMA, NMPA, PMDA, MFDS, HSA, ANVISA and Health Canada for the production and testing of a wide array of biologics.
-
Global Compliance
$Oversees global quality system and audit, IT quality, internal compliance, and risk analytics functions. This team embeds quality and compliance across the entire organization to ensure the products we manufacture are of the highest efficacy and safety standards and in line with your expectations.
-
Quality Assurance
$Global systems meet regulatory standards, ingrained commitment to quality from CEO to employees, harmonized QA across worldwide sites for biologics and vaccines production.
-
Quality Control
$Regulatory compliant, in-house, QC labs support all clinical and commercial GMP sites pre- and post-production, ensuring top-quality testing for products and oversight of other critical functions (e.g., environmental monitoring, cleaning validations, instrument life-cycle and sample/retain management and audits).
-
Regulatory Affairs
$Our experienced regulatory affairs team supports our client’s CMC dossier, drug filing and registration needs. Since 2015 this team has supported 550+ INDs, CTAs, BLAs, MAAs, NDAs and EUAs, and written 200+ Module 3 CMC packages on behalf of our global clients.
Global Compliance$Oversees global quality system and audit, IT quality, internal compliance, and risk analytics functions. This team embeds quality and compliance across the entire organization to ensure the products we manufacture are of the highest efficacy and safety standards and in line with your expectations.
Global Compliance
Oversees global quality system and audit, IT quality, internal compliance, and risk analytics functions. This team embeds quality and compliance across the entire organization to ensure the products we manufacture are of the highest efficacy and safety standards and in line with your expectations.
Learn more
Quality Assurance$Global systems meet regulatory standards, ingrained commitment to quality from CEO to employees, harmonized QA across worldwide sites for biologics and vaccines production.
Quality Assurance
Global systems meet regulatory standards, ingrained commitment to quality from CEO to employees, harmonized QA across worldwide sites for biologics and vaccines production.
Learn more
Quality Control$Regulatory compliant, in-house, QC labs support all clinical and commercial GMP sites pre- and post-production, ensuring top-quality testing for products and oversight of other critical functions (e.g., environmental monitoring, cleaning validations, instrument life-cycle and sample/retain management and audits).
Quality Control
Regulatory compliant, in-house, QC labs support all clinical and commercial GMP sites pre- and post-production, ensuring top-quality testing for products and oversight of other critical functions (e.g., environmental monitoring, cleaning validations, instrument life-cycle and sample/retain management and audits).
Learn more
Regulatory Affairs$Our experienced regulatory affairs team supports our client’s CMC dossier, drug filing and registration needs. Since 2015 this team has supported 550+ INDs, CTAs, BLAs, MAAs, NDAs and EUAs, and written 200+ Module 3 CMC packages on behalf of our global clients.
Regulatory Affairs
Our experienced regulatory affairs team supports our client’s CMC dossier, drug filing and registration needs. Since 2015 this team has supported 550+ INDs, CTAs, BLAs, MAAs, NDAs and EUAs, and written 200+ Module 3 CMC packages on behalf of our global clients.
Learn more
Featured Platforms
Integrated Platforms$Comprehensive, high-quality, end-to-end solutions driving efficiency, decreasing time to clinic and reducing project risks from concept to commercialization.
Target to Lead$Providing expertise, highly efficient tailored solutions, state-of-the-art technologies and world-class facilities for the engineering, generation, and optimization of antibodies and other biologics from target identification to final lead selection.
Target to Lead
Providing expertise, highly efficient tailored solutions, state-of-the-art technologies and world-class facilities for the engineering, generation, and optimization of antibodies and other biologics from target identification to final lead selection.
Learn more
DNA to IND$Providing industry-leading 10-month (or less) DNA to IND timeline for biologics by leveraging our single-source, high-quality, and well-vetted development platform across all CMC activities.
DNA to IND
Providing industry-leading 10-month (or less) DNA to IND timeline for biologics by leveraging our single-source, high-quality, and well-vetted development platform across all CMC activities.
Learn more
IND to BLA$Streamlined late-phase development and manufacturing services, ensuring BLA filing in 15 months or less, with global commercialization support through our highly-vetted development platforms.
IND to BLA
Streamlined late-phase development and manufacturing services, ensuring BLA filing in 15 months or less, with global commercialization support through our highly-vetted development platforms.
Learn more
Discovery Technologies$A full spectrum of discovery services and technologies for the engineering, generation, characterization, optimization and selection of high-potency novel antibody therapeutics.
Bispecific and Multispecific Antibodies – WuXiBody™$The WuXiBody platform for the generation of bispecific and multispecific antibodies speeds up drug development by 6‒18 months and cuts production costs. Assembly of mAb sequence pairs into various formats with different valency optimizes flexibility.
Bispecific and Multispecific Antibodies - WuXiBody™
The WuXiBody platform for the generation of bispecific and multispecific antibodies speeds up drug development by 6‒18 months and cuts production costs. Assembly of mAb sequence pairs into various formats with different valency optimizes flexibility.
Learn more
Rapid Research Material Generation – WuXian™$Custom protein generation services, producing high-quality, research-grade proteins/antibodies by using our industry-leading team of cell culture, purification and analytical experts and high-throughput, cost-effective production technologies.
Rapid Research Material Generation - WuXian™
Custom protein generation services, producing high-quality, research-grade proteins/antibodies by using our industry-leading team of cell culture, purification and analytical experts and high-throughput, cost-effective production technologies.
Learn more
Development Technologies$Cutting-edge bioprocessing platforms and technologies designed to enable high-quality biologics to enter clinical trials faster, more efficiently and more cost-effectively.
Ultra-Intensified Fed-batch platform – WuXiUI™$Ultra-intensified fed-batch bioprocessing platform utilizes an intermittent perfusion approach to achieve 3-6-fold higher productivity and 60 – 80% reduction in manufacturing cost of goods compared to traditional fed-batch processes.
Ultra-Intensified Fed-batch platform - WuXiUI™
Ultra-intensified fed-batch bioprocessing platform utilizes an intermittent perfusion approach to achieve 3-6-fold higher productivity and 60 – 80% reduction in manufacturing cost of goods compared to traditional fed-batch processes.
Learn more
Cell Line Development – WuXia™$Proven, high-yielding (up to 11 g/L) and high-quality cell line development platform, accepted by regulatory agencies worldwide.
Cell Line Development - WuXia™
Proven, high-yielding (up to 11 g/L) and high-quality cell line development platform, accepted by regulatory agencies worldwide.
Learn more
Continuous Bioprocessing – WuXiUP™$This ultra-high productivity continuous bioprocessing platform, achieves 5-15X greater productivity, delivering high-yield, quality drug products with flexibility and cost-effectiveness through intensified perfusion culture, continuous harvest and optional downstream continuous product capture step.
Continuous Bioprocessing - WuXiUP™
This ultra-high productivity continuous bioprocessing platform, achieves 5-15X greater productivity, delivering high-yield, quality drug products with flexibility and cost-effectiveness through intensified perfusion culture, continuous harvest and optional downstream continuous product capture step.
Learn more
ADC Development Platform – WuXiDAR4™$Our drug-to-antibody ratio and enrichment technology greatly enhances DAR4 (four payload molecules per mAb) percentage in the final ADC product and improves conjugation efficiency.
ADC Development Platform - WuXiDAR4™
Our drug-to-antibody ratio and enrichment technology greatly enhances DAR4 (four payload molecules per mAb) percentage in the final ADC product and improves conjugation efficiency.
Learn more
High Concentration & HTP DP Platform – WuXiHigh™$Advanced high throughput formulation platform for development of high concentration biologics drug products using distinctive viscosity reducers and synergistic excipient combinations to enhance formulation stability and reduce viscosity.
High Concentration & HTP DP Platform - WuXiHigh™
Advanced high throughput formulation platform for development of high concentration biologics drug products using distinctive viscosity reducers and synergistic excipient combinations to enhance formulation stability and reduce viscosity.
Learn more
Monitoring and Predictive Control – PatroLab$Real-time monitoring, predictive modeling, and automated process control synthesized into one digital platform.
Monitoring and Predictive Control - PatroLab
Real-time monitoring, predictive modeling, and automated process control synthesized into one digital platform.
Learn more
Manufacturing Technologies$Advanced biomanufacturing platforms empower our global healthcare partners to deliver biologics to the clinic and on to the market for the benefit of patients worldwide.
-
Single-Use Bioreactors
$We operate several of the world’s largest single-use bioreactor facilities for biologics manufacturing, leveraging the risk reduction, flexibility, cost-effectiveness, and eco-friendliness offered by these systems.
-
Scale-Out Biomanufacturing
$Helping to pioneer this biomanufacturing strategy for higher volume production, we can help you reduce risk and increase manufacturing flexibility across the entire product lifecycle by using multiple, same-scale bioreactors to meet clinical and market demand.
-
Robotic Aseptic Filling
$Reducing manufacturing risk through the use of this fully programmable, robotic, gloveless, isolator-based technology for advanced aseptic drug product fill processing. These systems provide extensive flexibility to support complex fills across a wide range of biologics and container closure systems.
-
Continuous Manufacturing Process
$Combining intensified perfusion culture (IPC) and continuous direct product capture (CDPC), and advanced equipment for increased productivity and cost reduction.
Single-Use Bioreactors$We operate several of the world’s largest single-use bioreactor facilities for biologics manufacturing, leveraging the risk reduction, flexibility, cost-effectiveness, and eco-friendliness offered by these systems.
Single-Use Bioreactors
We operate several of the world’s largest single-use bioreactor facilities for biologics manufacturing, leveraging the risk reduction, flexibility, cost-effectiveness, and eco-friendliness offered by these systems.
Learn more
Scale-Out Biomanufacturing$Helping to pioneer this biomanufacturing strategy for higher volume production, we can help you reduce risk and increase manufacturing flexibility across the entire product lifecycle by using multiple, same-scale bioreactors to meet clinical and market demand.
Scale-Out Biomanufacturing
Helping to pioneer this biomanufacturing strategy for higher volume production, we can help you reduce risk and increase manufacturing flexibility across the entire product lifecycle by using multiple, same-scale bioreactors to meet clinical and market demand.
Learn more
Robotic Aseptic Filling$Reducing manufacturing risk through the use of this fully programmable, robotic, gloveless, isolator-based technology for advanced aseptic drug product fill processing. These systems provide extensive flexibility to support complex fills across a wide range of biologics and container closure systems.
Robotic Aseptic Filling
Reducing manufacturing risk through the use of this fully programmable, robotic, gloveless, isolator-based technology for advanced aseptic drug product fill processing. These systems provide extensive flexibility to support complex fills across a wide range of biologics and container closure systems.
Learn more
Continuous Manufacturing Process$Combining intensified perfusion culture (IPC) and continuous direct product capture (CDPC), and advanced equipment for increased productivity and cost reduction.
Continuous Manufacturing Process
Combining intensified perfusion culture (IPC) and continuous direct product capture (CDPC), and advanced equipment for increased productivity and cost reduction.
Learn more
Animal Health Technologies$One-stop solution for superior animal health outcomes.
Animal Health Technologies$We offer CMC-compliant, one-stop solution for animal health, to support taking drug substance and drug product from research to manufacturing.
Animal Health Technologies
We offer CMC-compliant, one-stop solution for animal health, to support taking drug substance and drug product from research to manufacturing.
Learn more
Sustainability
Sustainability
Careers
What We Value
Meet our people
Join us
Investors
Investor Events
News & Resources
WuXi Biologics
Offering End-to-End Solutions

-
About Us

About Us
-
Services & Capabilities
-
Production Systems
-
Mammalian
$Our expertise spans discovery, development, and cGMP manufacture of biologics from mammalian cell culture. Leveraging 6 discovery platforms, a top-tier CMC development team, and an extensive supply chain, we deliver seamless programs for all your biologics drug development needs.

Mammalian
Our expertise spans discovery, development, and cGMP manufacture of biologics from mammalian cell culture. Leveraging 6 discovery platforms, a top-tier CMC development team, and an extensive supply chain, we deliver seamless programs for all your biologics drug development needs.
-
Microbial
$Comprehensive CMC development and cGMP manufacturing microbial fermentation platform. E. coli and yeast-based expression systems for the production of plasmid DNA and recombinant proteins.

Microbial
Comprehensive CMC development and cGMP manufacturing microbial fermentation platform. E. coli and yeast-based expression systems for the production of plasmid DNA and recombinant proteins.
-
Capabilities
-
Research
$Integrated Discovery Platform From Concept to IND

Research
Integrated Discovery Platform From Concept to IND
-
Back
-
Antibody Discovery Services
$We offer customized antibody discovery platforms for monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), multispecific antibodies (msAbs), immunocytokines, and other therapeutic modalities, to accelerate biology-driven lead identification.
Antibody Discovery Services
We offer customized antibody discovery platforms for monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), multispecific antibodies (msAbs), immunocytokines, and other therapeutic modalities, to accelerate biology-driven lead identification.
Learn more
-
Protein Production & Engineering Services
$At WuXi Biologics, we specialize in the production and engineering of monoclonal, bispecific, and multi-specific antibodies, fusion-proteins, cytokines, enzymes, and novel biologics. With industry-leading expertise, state-of-the-art facilities and proprietary technologies, we offer our customers high-quality protein engineering and production services for research use.
Protein Production & Engineering Services
At WuXi Biologics, we specialize in the production and engineering of monoclonal, bispecific, and multi-specific antibodies, fusion-proteins, cytokines, enzymes, and novel biologics. With industry-leading expertise, state-of-the-art facilities and proprietary technologies, we offer our customers high-quality protein engineering and production services for research use.
Learn more
-
Protein Characterization Services
$At WuXi Biologics, we provide comprehensive protein characterization testing to help you triage and optimize your lead candidates. Our integrated protein characterization and analytics platform includes purity/impurity testing, structure characterization assessment, including MS-based protein ID and post-translational modification analysis, and function testing (e.g., SPR/ELISA/cell-based activity assays).
Protein Characterization Services
At WuXi Biologics, we provide comprehensive protein characterization testing to help you triage and optimize your lead candidates. Our integrated protein characterization and analytics platform includes purity/impurity testing, structure characterization assessment, including MS-based protein ID and post-translational modification analysis, and function testing (e.g., SPR/ELISA/cell-based activity assays).
Learn more
-
In Vitro Assays Services
$Leveraging advanced in vitro assay technologies such as cellular, biochemical, molecular, immune, and Fc effector function assays, we deliver reproducible, high-quality results with data interpretation to support biologics discovery and development.
In Vitro Assays Services
Leveraging advanced in vitro assay technologies such as cellular, biochemical, molecular, immune, and Fc effector function assays, we deliver reproducible, high-quality results with data interpretation to support biologics discovery and development.
Learn more
-
In Vivo Pharmacology Services
$Our multi-species in vivo pharmacology services provide science-driven solutions for preclinical studies, including pharmacokinetic (PK) and pharmacodynamic (PD) evaluations, efficacy models, toxicology studies, and immunohistology.
In Vivo Pharmacology Services
Our multi-species in vivo pharmacology services provide science-driven solutions for preclinical studies, including pharmacokinetic (PK) and pharmacodynamic (PD) evaluations, efficacy models, toxicology studies, and immunohistology.
Learn more
-
Subsidiaries
-
-
-
Development
$Utilizing one of the world’s largest and most experienced development teams, we have the resources, technologies and expertise to drive your program toward IND and BLA in the most efficient and cost-effective manner.

Development
Utilizing one of the world’s largest and most experienced development teams, we have the resources, technologies and expertise to drive your program toward IND and BLA in the most efficient and cost-effective manner.
-
Back
-
Mammalian Cell Line Development
$Generate stable CHO and HEK293 cell lines at industry-leading speed and global scale.
Mammalian Cell Line Development
Generate stable CHO and HEK293 cell lines at industry-leading speed and global scale.
Learn more
-
Microbial Strain Development
$Generate microbial strains and viral production systems from a variety of modalities.
Microbial Strain Development
Generate microbial strains and viral production systems from a variety of modalities.
Learn more
-
Analytical Sciences
$Our extensive analytical testing services offer top-tier expertise in method development for in-process, release, and stability assays, and support of cell line, process, and formulation development activities, product characterization, developability assessments and other key IND- and BLA-enabling studies.
Analytical Sciences
Our extensive analytical testing services offer top-tier expertise in method development for in-process, release, and stability assays, and support of cell line, process, and formulation development activities, product characterization, developability assessments and other key IND- and BLA-enabling studies.
Learn more
-
Process Development & Scale Up
$Multiple upstream and downstream PD labs facilitate the establishment and scale-up of fed-batch, intensified fed-batch, and continuous manufacturing approaches for diverse biotherapeutic modalities in both early and late-stage development.
Process Development & Scale Up
Multiple upstream and downstream PD labs facilitate the establishment and scale-up of fed-batch, intensified fed-batch, and continuous manufacturing approaches for diverse biotherapeutic modalities in both early and late-stage development.
Learn more
-
Late-Stage Development
$Late-stage development scales processes for commercialization, culminating in biologic characterization, characterization, and validation.
Late-Stage Development
Late-stage development scales processes for commercialization, culminating in biologic characterization, characterization, and validation.
Learn more
-
Process Characterization
$Process characterization supports drug substance production within a data-driven framework that streamlines PPQ and meets global compliance requirements.
Process Characterization
Process characterization supports drug substance production within a data-driven framework that streamlines PPQ and meets global compliance requirements.
Learn more
-
Formulation & Drug Product Development
$We provide advanced drug product development services spanning biologics, vaccines, and small molecules, with expertise in formulating clinical and commercial products in liquid, frozen, and lyophilized forms, compatible with various container closure systems such as vials, prefilled syringes, and other combination product types.
Formulation & Drug Product Development
We provide advanced drug product development services spanning biologics, vaccines, and small molecules, with expertise in formulating clinical and commercial products in liquid, frozen, and lyophilized forms, compatible with various container closure systems such as vials, prefilled syringes, and other combination product types.
Learn more
-
Cell Banking & Characterization
$Offering in-house, one-stop cell banking and cell line characterization services, compliant with global GMP regulations and ICH guidelines, we operate over 20 cGMP cell banking suites ensuring capacity availability and timely execution of this critical CMC development activity.
Cell Banking & Characterization
Offering in-house, one-stop cell banking and cell line characterization services, compliant with global GMP regulations and ICH guidelines, we operate over 20 cGMP cell banking suites ensuring capacity availability and timely execution of this critical CMC development activity.
Learn more
-
Viral Clearance
$Our extensive experience and expertise, along with EMA, ISO (CNAS), and CMA-certified laboratories, and exceptional track record for IND- and BLA-enabling viral clearance study acceptance by global regulatory agencies, form the cornerstones for this pivotal aspect of any CMC development program.
Viral Clearance
Our extensive experience and expertise, along with EMA, ISO (CNAS), and CMA-certified laboratories, and exceptional track record for IND- and BLA-enabling viral clearance study acceptance by global regulatory agencies, form the cornerstones for this pivotal aspect of any CMC development program.
Learn more
-
Regulatory Support
$Our experienced regulatory affairs team supports drug filing and registration with over 370 INDs/CTAs, 20+ BLAs/MAAs/NDAs/EUAs, and 150 Module 3 CMC packages since 2015.
Regulatory Support
Our experienced regulatory affairs team supports drug filing and registration with over 370 INDs/CTAs, 20+ BLAs/MAAs/NDAs/EUAs, and 150 Module 3 CMC packages since 2015.
Learn more
-
Subsidiaries
-
-
-
Manufacturing
$Multiple state-of-the-art, premier quality cGMP clinical- and commercial-scale drug substance (DS) and drug product (DP) facilities across four countries for the production of a wide array of biologics from both mammalian and microbial expression systems.

Manufacturing
Multiple state-of-the-art, premier quality cGMP clinical- and commercial-scale drug substance (DS) and drug product (DP) facilities across four countries for the production of a wide array of biologics from both mammalian and microbial expression systems.
-
Back
-
Clinical DS GMP Manufacturing
$Operating multiple high-quality, state-of-the-art clinical-scale cGMP facilities for biologics drug substance (DS) production utilizing both mammalian and microbial expression systems.
Clinical DS GMP Manufacturing
Operating multiple high-quality, state-of-the-art clinical-scale cGMP facilities for biologics drug substance (DS) production utilizing both mammalian and microbial expression systems.
Learn more
-
Clinical DP GMP Manufacturing
$Multiple, highly flexible clinical-scale drug product (DP) manufacturing facilities for the formulation, fill, labelling and packaging of biologics and parenterals under Current Good Manufacturing Practice (cGMP) conditions as defined by global regulatory agencies.
Clinical DP GMP Manufacturing
Multiple, highly flexible clinical-scale drug product (DP) manufacturing facilities for the formulation, fill, labelling and packaging of biologics and parenterals under Current Good Manufacturing Practice (cGMP) conditions as defined by global regulatory agencies.
Learn more
-
Commercial DS GMP Manufacturing
$We provide a global dual source manufacturing network that employs multiple large-scale drug substance (DS) GMP manufacturing facilities for the production of biologics utilizing our world-class operations and regulatory agency-approved quality systems.
Commercial DS GMP Manufacturing
We provide a global dual source manufacturing network that employs multiple large-scale drug substance (DS) GMP manufacturing facilities for the production of biologics utilizing our world-class operations and regulatory agency-approved quality systems.
Learn more
-
Commercial DP GMP Manufacturing
$Multiple large-scale drug product (DP) manufacturing facilities located across the globe for the high-quality formulation, fill, labelling and packaging of biologics, parenterals and placebo into a wide array of container closure systems.
Commercial DP GMP Manufacturing
Multiple large-scale drug product (DP) manufacturing facilities located across the globe for the high-quality formulation, fill, labelling and packaging of biologics, parenterals and placebo into a wide array of container closure systems.
Learn more
-
Subsidiaries
-
-
-
Testing
$We provide extensive expertise for in-process, characterization, release and stability method development and testing either in support of our integrated biologics development platforms or as standalone projects. Our wide-range of analytical and biosafety testing Centers of Excellence and regulatory agency-approved quality control (QC) laboratories are the backbone of every service we provide our clients.

Testing
We provide extensive expertise for in-process, characterization, release and stability method development and testing either in support of our integrated biologics development platforms or as standalone projects. Our wide-range of analytical and biosafety testing Centers of Excellence and regulatory agency-approved quality control (QC) laboratories are the backbone of every service we provide our clients.
-
Back
-
Biosafety Testing
$High quality, in-house and EMA, ISO (CNAS) and CMA certified biosafety testing facilities for adventitious agent screening of raw materials, cell lines and unprocessed bulk along with our extensive viral clearance capabilities is available to provide our clients with a single-source biosafety testing service offering.
Biosafety Testing
High quality, in-house and EMA, ISO (CNAS) and CMA certified biosafety testing facilities for adventitious agent screening of raw materials, cell lines and unprocessed bulk along with our extensive viral clearance capabilities is available to provide our clients with a single-source biosafety testing service offering.
Learn more
-
Analytical Testing
$We offer an extensive array of assay development and analytical testing services, including bioassay development and forensic investigation analysis, along with other key characterization and IND and BLA-enabling studies throughout the various phases of drug development – all tailored for your unique product and project needs.
Analytical Testing
We offer an extensive array of assay development and analytical testing services, including bioassay development and forensic investigation analysis, along with other key characterization and IND and BLA-enabling studies throughout the various phases of drug development – all tailored for your unique product and project needs.
Learn more
-
Bioassay Method Development Services
-
Product Characterization Service
-
Routine Analytical Testing Services
-
Centers of Excellence (CoE)
$Our CoEs support projects with specialized testing throughout the product lifecycle, expediting project timelines and ensuring analytical readiness for commercialization.
Centers of Excellence (CoE)
Our CoEs support projects with specialized testing throughout the product lifecycle, expediting project timelines and ensuring analytical readiness for commercialization.
Learn more
-
Global Quality Control (QC)
$Regulatory compliant, in-house, QC labs support all clinical and commercial GMP sites pre- and post-production, ensuring top-quality testing for products and oversight of other critical functions (e.g., environmental monitoring, cleaning validations, instrument life-cycle and sample/retain management and audits).
Global Quality Control (QC)
Regulatory compliant, in-house, QC labs support all clinical and commercial GMP sites pre- and post-production, ensuring top-quality testing for products and oversight of other critical functions (e.g., environmental monitoring, cleaning validations, instrument life-cycle and sample/retain management and audits).
Learn more
-
Subsidiaries
-
-
-
Quality
-
Quality & Regulatory
$We provide world-class quality systems, harmonized across our global manufacturing sites and approved by multiple global regulatory agencies, including the U.S. FDA, EMA, NMPA, PMDA, MFDS, HSA, ANVISA and Health Canada for the production and testing of a wide array of biologics.

Quality & Regulatory
We provide world-class quality systems, harmonized across our global manufacturing sites and approved by multiple global regulatory agencies, including the U.S. FDA, EMA, NMPA, PMDA, MFDS, HSA, ANVISA and Health Canada for the production and testing of a wide array of biologics.
-
Back
-
Global Compliance
$Oversees global quality system and audit, IT quality, internal compliance, and risk analytics functions. This team embeds quality and compliance across the entire organization to ensure the products we manufacture are of the highest efficacy and safety standards and in line with your expectations.
Global Compliance
Oversees global quality system and audit, IT quality, internal compliance, and risk analytics functions. This team embeds quality and compliance across the entire organization to ensure the products we manufacture are of the highest efficacy and safety standards and in line with your expectations.
Learn more
-
Quality Assurance
$Global systems meet regulatory standards, ingrained commitment to quality from CEO to employees, harmonized QA across worldwide sites for biologics and vaccines production.
Quality Assurance
Global systems meet regulatory standards, ingrained commitment to quality from CEO to employees, harmonized QA across worldwide sites for biologics and vaccines production.
Learn more
-
Quality Control
$Regulatory compliant, in-house, QC labs support all clinical and commercial GMP sites pre- and post-production, ensuring top-quality testing for products and oversight of other critical functions (e.g., environmental monitoring, cleaning validations, instrument life-cycle and sample/retain management and audits).
Quality Control
Regulatory compliant, in-house, QC labs support all clinical and commercial GMP sites pre- and post-production, ensuring top-quality testing for products and oversight of other critical functions (e.g., environmental monitoring, cleaning validations, instrument life-cycle and sample/retain management and audits).
Learn more
-
Regulatory Affairs
$Our experienced regulatory affairs team supports our client’s CMC dossier, drug filing and registration needs. Since 2015 this team has supported 550+ INDs, CTAs, BLAs, MAAs, NDAs and EUAs, and written 200+ Module 3 CMC packages on behalf of our global clients.
Regulatory Affairs
Our experienced regulatory affairs team supports our client’s CMC dossier, drug filing and registration needs. Since 2015 this team has supported 550+ INDs, CTAs, BLAs, MAAs, NDAs and EUAs, and written 200+ Module 3 CMC packages on behalf of our global clients.
Learn more
-
Subsidiaries
-
-
-
Featured Platforms
-
Integrated Platforms
$Comprehensive, high-quality, end-to-end solutions driving efficiency, decreasing time to clinic and reducing project risks from concept to commercialization.

Integrated Platforms
Comprehensive, high-quality, end-to-end solutions driving efficiency, decreasing time to clinic and reducing project risks from concept to commercialization.
-
Back
-
Target to Lead
$Providing expertise, highly efficient tailored solutions, state-of-the-art technologies and world-class facilities for the engineering, generation, and optimization of antibodies and other biologics from target identification to final lead selection.
Target to Lead
Providing expertise, highly efficient tailored solutions, state-of-the-art technologies and world-class facilities for the engineering, generation, and optimization of antibodies and other biologics from target identification to final lead selection.
Learn more
-
DNA to IND
$Providing industry-leading 10-month (or less) DNA to IND timeline for biologics by leveraging our single-source, high-quality, and well-vetted development platform across all CMC activities.
DNA to IND
Providing industry-leading 10-month (or less) DNA to IND timeline for biologics by leveraging our single-source, high-quality, and well-vetted development platform across all CMC activities.
Learn more
-
IND to BLA
$Streamlined late-phase development and manufacturing services, ensuring BLA filing in 15 months or less, with global commercialization support through our highly-vetted development platforms.
IND to BLA
Streamlined late-phase development and manufacturing services, ensuring BLA filing in 15 months or less, with global commercialization support through our highly-vetted development platforms.
Learn more
-
Subsidiaries
-
-
-
Discovery Technologies
$A full spectrum of discovery services and technologies for the engineering, generation, characterization, optimization and selection of high-potency novel antibody therapeutics.

Discovery Technologies
A full spectrum of discovery services and technologies for the engineering, generation, characterization, optimization and selection of high-potency novel antibody therapeutics.
-
Development Technologies
$Cutting-edge bioprocessing platforms and technologies designed to enable high-quality biologics to enter clinical trials faster, more efficiently and more cost-effectively.

Development Technologies
Cutting-edge bioprocessing platforms and technologies designed to enable high-quality biologics to enter clinical trials faster, more efficiently and more cost-effectively.
-
Back
-
Ultra-Intensified Fed-batch platform – WuXiUI™
$Ultra-intensified fed-batch bioprocessing platform utilizes an intermittent perfusion approach to achieve 3-6-fold higher productivity and 60 – 80% reduction in manufacturing cost of goods compared to traditional fed-batch processes.
Ultra-Intensified Fed-batch platform - WuXiUI™
Ultra-intensified fed-batch bioprocessing platform utilizes an intermittent perfusion approach to achieve 3-6-fold higher productivity and 60 – 80% reduction in manufacturing cost of goods compared to traditional fed-batch processes.
Learn more
-
Cell Line Development – WuXia™
$Proven, high-yielding (up to 11 g/L) and high-quality cell line development platform, accepted by regulatory agencies worldwide.
Cell Line Development - WuXia™
Proven, high-yielding (up to 11 g/L) and high-quality cell line development platform, accepted by regulatory agencies worldwide.
Learn more
-
Continuous Bioprocessing – WuXiUP™
$This ultra-high productivity continuous bioprocessing platform, achieves 5-15X greater productivity, delivering high-yield, quality drug products with flexibility and cost-effectiveness through intensified perfusion culture, continuous harvest and optional downstream continuous product capture step.
Continuous Bioprocessing - WuXiUP™
This ultra-high productivity continuous bioprocessing platform, achieves 5-15X greater productivity, delivering high-yield, quality drug products with flexibility and cost-effectiveness through intensified perfusion culture, continuous harvest and optional downstream continuous product capture step.
Learn more
-
ADC Development Platform – WuXiDAR4™
$Our drug-to-antibody ratio and enrichment technology greatly enhances DAR4 (four payload molecules per mAb) percentage in the final ADC product and improves conjugation efficiency.
ADC Development Platform - WuXiDAR4™
Our drug-to-antibody ratio and enrichment technology greatly enhances DAR4 (four payload molecules per mAb) percentage in the final ADC product and improves conjugation efficiency.
Learn more
-
High Concentration & HTP DP Platform – WuXiHigh™
$Advanced high throughput formulation platform for development of high concentration biologics drug products using distinctive viscosity reducers and synergistic excipient combinations to enhance formulation stability and reduce viscosity.
High Concentration & HTP DP Platform - WuXiHigh™
Advanced high throughput formulation platform for development of high concentration biologics drug products using distinctive viscosity reducers and synergistic excipient combinations to enhance formulation stability and reduce viscosity.
Learn more
-
Monitoring and Predictive Control – PatroLab
$Real-time monitoring, predictive modeling, and automated process control synthesized into one digital platform.
Monitoring and Predictive Control - PatroLab
Real-time monitoring, predictive modeling, and automated process control synthesized into one digital platform.
Learn more
-
Subsidiaries
-
-
-
Manufacturing Technologies
$Advanced biomanufacturing platforms empower our global healthcare partners to deliver biologics to the clinic and on to the market for the benefit of patients worldwide.

Manufacturing Technologies
Advanced biomanufacturing platforms empower our global healthcare partners to deliver biologics to the clinic and on to the market for the benefit of patients worldwide.
-
Back
-
Single-Use Bioreactors
$We operate several of the world’s largest single-use bioreactor facilities for biologics manufacturing, leveraging the risk reduction, flexibility, cost-effectiveness, and eco-friendliness offered by these systems.
Single-Use Bioreactors
We operate several of the world’s largest single-use bioreactor facilities for biologics manufacturing, leveraging the risk reduction, flexibility, cost-effectiveness, and eco-friendliness offered by these systems.
Learn more
-
Scale-Out Biomanufacturing
$Helping to pioneer this biomanufacturing strategy for higher volume production, we can help you reduce risk and increase manufacturing flexibility across the entire product lifecycle by using multiple, same-scale bioreactors to meet clinical and market demand.
Scale-Out Biomanufacturing
Helping to pioneer this biomanufacturing strategy for higher volume production, we can help you reduce risk and increase manufacturing flexibility across the entire product lifecycle by using multiple, same-scale bioreactors to meet clinical and market demand.
Learn more
-
Robotic Aseptic Filling
$Reducing manufacturing risk through the use of this fully programmable, robotic, gloveless, isolator-based technology for advanced aseptic drug product fill processing. These systems provide extensive flexibility to support complex fills across a wide range of biologics and container closure systems.
Robotic Aseptic Filling
Reducing manufacturing risk through the use of this fully programmable, robotic, gloveless, isolator-based technology for advanced aseptic drug product fill processing. These systems provide extensive flexibility to support complex fills across a wide range of biologics and container closure systems.
Learn more
-
Continuous Manufacturing Process
$Combining intensified perfusion culture (IPC) and continuous direct product capture (CDPC), and advanced equipment for increased productivity and cost reduction.
Continuous Manufacturing Process
Combining intensified perfusion culture (IPC) and continuous direct product capture (CDPC), and advanced equipment for increased productivity and cost reduction.
Learn more
-
Subsidiaries
-
-
-
Animal Health Technologies
$One-stop solution for superior animal health outcomes.

Animal Health Technologies
One-stop solution for superior animal health outcomes.
-
Sustainability

Sustainability
-
Careers

Careers
-
Investors

Investors
-
News & Resources

News & Resources


中文 / CN
Deutsch / DE
日本語 / JP
한글 / KR
Contact Us
菜单
-
Home
-
About Us
-
Services & Capabilities
-
Production Systems
-
Mammalian
$Our expertise spans discovery, development, and cGMP manufacture of biologics from mammalian cell culture. Leveraging 6 discovery platforms, a top-tier CMC development team, and an extensive supply chain, we deliver seamless programs for all your biologics drug development needs.
-
Microbial
$Comprehensive CMC development and cGMP manufacturing microbial fermentation platform. E. coli and yeast-based expression systems for the production of plasmid DNA and recombinant proteins.
-
Capabilities
-
Research
$Integrated Discovery Platform From Concept to IND
-
Antibody Discovery Services
$We offer customized antibody discovery platforms for monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), multispecific antibodies (msAbs), immunocytokines, and other therapeutic modalities, to accelerate biology-driven lead identification.
Antibody Discovery Services
We offer customized antibody discovery platforms for monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), multispecific antibodies (msAbs), immunocytokines, and other therapeutic modalities, to accelerate biology-driven lead identification.
Learn more
-
Protein Production & Engineering Services
$At WuXi Biologics, we specialize in the production and engineering of monoclonal, bispecific, and multi-specific antibodies, fusion-proteins, cytokines, enzymes, and novel biologics. With industry-leading expertise, state-of-the-art facilities and proprietary technologies, we offer our customers high-quality protein engineering and production services for research use.
Protein Production & Engineering Services
At WuXi Biologics, we specialize in the production and engineering of monoclonal, bispecific, and multi-specific antibodies, fusion-proteins, cytokines, enzymes, and novel biologics. With industry-leading expertise, state-of-the-art facilities and proprietary technologies, we offer our customers high-quality protein engineering and production services for research use.
Learn more
-
Protein Characterization Services
$At WuXi Biologics, we provide comprehensive protein characterization testing to help you triage and optimize your lead candidates. Our integrated protein characterization and analytics platform includes purity/impurity testing, structure characterization assessment, including MS-based protein ID and post-translational modification analysis, and function testing (e.g., SPR/ELISA/cell-based activity assays).
Protein Characterization Services
At WuXi Biologics, we provide comprehensive protein characterization testing to help you triage and optimize your lead candidates. Our integrated protein characterization and analytics platform includes purity/impurity testing, structure characterization assessment, including MS-based protein ID and post-translational modification analysis, and function testing (e.g., SPR/ELISA/cell-based activity assays).
Learn more
-
In Vitro Assays Services
$Leveraging advanced in vitro assay technologies such as cellular, biochemical, molecular, immune, and Fc effector function assays, we deliver reproducible, high-quality results with data interpretation to support biologics discovery and development.
In Vitro Assays Services
Leveraging advanced in vitro assay technologies such as cellular, biochemical, molecular, immune, and Fc effector function assays, we deliver reproducible, high-quality results with data interpretation to support biologics discovery and development.
Learn more
-
In Vivo Pharmacology Services
$Our multi-species in vivo pharmacology services provide science-driven solutions for preclinical studies, including pharmacokinetic (PK) and pharmacodynamic (PD) evaluations, efficacy models, toxicology studies, and immunohistology.
In Vivo Pharmacology Services
Our multi-species in vivo pharmacology services provide science-driven solutions for preclinical studies, including pharmacokinetic (PK) and pharmacodynamic (PD) evaluations, efficacy models, toxicology studies, and immunohistology.
Learn more
-
Development
$Utilizing one of the world’s largest and most experienced development teams, we have the resources, technologies and expertise to drive your program toward IND and BLA in the most efficient and cost-effective manner.
-
Mammalian Cell Line Development
$Generate stable CHO and HEK293 cell lines at industry-leading speed and global scale.
Mammalian Cell Line Development
Generate stable CHO and HEK293 cell lines at industry-leading speed and global scale.
Learn more
-
Microbial Strain Development
$Generate microbial strains and viral production systems from a variety of modalities.
Microbial Strain Development
Generate microbial strains and viral production systems from a variety of modalities.
Learn more
-
Analytical Sciences
$Our extensive analytical testing services offer top-tier expertise in method development for in-process, release, and stability assays, and support of cell line, process, and formulation development activities, product characterization, developability assessments and other key IND- and BLA-enabling studies.
Analytical Sciences
Our extensive analytical testing services offer top-tier expertise in method development for in-process, release, and stability assays, and support of cell line, process, and formulation development activities, product characterization, developability assessments and other key IND- and BLA-enabling studies.
Learn more
-
Process Development & Scale Up
$Multiple upstream and downstream PD labs facilitate the establishment and scale-up of fed-batch, intensified fed-batch, and continuous manufacturing approaches for diverse biotherapeutic modalities in both early and late-stage development.
Process Development & Scale Up
Multiple upstream and downstream PD labs facilitate the establishment and scale-up of fed-batch, intensified fed-batch, and continuous manufacturing approaches for diverse biotherapeutic modalities in both early and late-stage development.
Learn more
-
Late-Stage Development
$Late-stage development scales processes for commercialization, culminating in biologic characterization, characterization, and validation.
Late-Stage Development
Late-stage development scales processes for commercialization, culminating in biologic characterization, characterization, and validation.
Learn more
-
Process Characterization
$Process characterization supports drug substance production within a data-driven framework that streamlines PPQ and meets global compliance requirements.
Process Characterization
Process characterization supports drug substance production within a data-driven framework that streamlines PPQ and meets global compliance requirements.
Learn more
-
Formulation & Drug Product Development
$We provide advanced drug product development services spanning biologics, vaccines, and small molecules, with expertise in formulating clinical and commercial products in liquid, frozen, and lyophilized forms, compatible with various container closure systems such as vials, prefilled syringes, and other combination product types.
Formulation & Drug Product Development
We provide advanced drug product development services spanning biologics, vaccines, and small molecules, with expertise in formulating clinical and commercial products in liquid, frozen, and lyophilized forms, compatible with various container closure systems such as vials, prefilled syringes, and other combination product types.
Learn more
-
Cell Banking & Characterization
$Offering in-house, one-stop cell banking and cell line characterization services, compliant with global GMP regulations and ICH guidelines, we operate over 20 cGMP cell banking suites ensuring capacity availability and timely execution of this critical CMC development activity.
Cell Banking & Characterization
Offering in-house, one-stop cell banking and cell line characterization services, compliant with global GMP regulations and ICH guidelines, we operate over 20 cGMP cell banking suites ensuring capacity availability and timely execution of this critical CMC development activity.
Learn more
-
Viral Clearance
$Our extensive experience and expertise, along with EMA, ISO (CNAS), and CMA-certified laboratories, and exceptional track record for IND- and BLA-enabling viral clearance study acceptance by global regulatory agencies, form the cornerstones for this pivotal aspect of any CMC development program.
Viral Clearance
Our extensive experience and expertise, along with EMA, ISO (CNAS), and CMA-certified laboratories, and exceptional track record for IND- and BLA-enabling viral clearance study acceptance by global regulatory agencies, form the cornerstones for this pivotal aspect of any CMC development program.
Learn more
-
Regulatory Support
$Our experienced regulatory affairs team supports drug filing and registration with over 370 INDs/CTAs, 20+ BLAs/MAAs/NDAs/EUAs, and 150 Module 3 CMC packages since 2015.
Regulatory Support
Our experienced regulatory affairs team supports drug filing and registration with over 370 INDs/CTAs, 20+ BLAs/MAAs/NDAs/EUAs, and 150 Module 3 CMC packages since 2015.
Learn more
-
Manufacturing
$Multiple state-of-the-art, premier quality cGMP clinical- and commercial-scale drug substance (DS) and drug product (DP) facilities across four countries for the production of a wide array of biologics from both mammalian and microbial expression systems.
-
Clinical DS GMP Manufacturing
$Operating multiple high-quality, state-of-the-art clinical-scale cGMP facilities for biologics drug substance (DS) production utilizing both mammalian and microbial expression systems.
Clinical DS GMP Manufacturing
Operating multiple high-quality, state-of-the-art clinical-scale cGMP facilities for biologics drug substance (DS) production utilizing both mammalian and microbial expression systems.
Learn more
-
Clinical DP GMP Manufacturing
$Multiple, highly flexible clinical-scale drug product (DP) manufacturing facilities for the formulation, fill, labelling and packaging of biologics and parenterals under Current Good Manufacturing Practice (cGMP) conditions as defined by global regulatory agencies.
Clinical DP GMP Manufacturing
Multiple, highly flexible clinical-scale drug product (DP) manufacturing facilities for the formulation, fill, labelling and packaging of biologics and parenterals under Current Good Manufacturing Practice (cGMP) conditions as defined by global regulatory agencies.
Learn more
-
Commercial DS GMP Manufacturing
$We provide a global dual source manufacturing network that employs multiple large-scale drug substance (DS) GMP manufacturing facilities for the production of biologics utilizing our world-class operations and regulatory agency-approved quality systems.
Commercial DS GMP Manufacturing
We provide a global dual source manufacturing network that employs multiple large-scale drug substance (DS) GMP manufacturing facilities for the production of biologics utilizing our world-class operations and regulatory agency-approved quality systems.
Learn more
-
Commercial DP GMP Manufacturing
$Multiple large-scale drug product (DP) manufacturing facilities located across the globe for the high-quality formulation, fill, labelling and packaging of biologics, parenterals and placebo into a wide array of container closure systems.
Commercial DP GMP Manufacturing
Multiple large-scale drug product (DP) manufacturing facilities located across the globe for the high-quality formulation, fill, labelling and packaging of biologics, parenterals and placebo into a wide array of container closure systems.
Learn more
-
Testing
$We provide extensive expertise for in-process, characterization, release and stability method development and testing either in support of our integrated biologics development platforms or as standalone projects. Our wide-range of analytical and biosafety testing Centers of Excellence and regulatory agency-approved quality control (QC) laboratories are the backbone of every service we provide our clients.
-
Biosafety Testing
$High quality, in-house and EMA, ISO (CNAS) and CMA certified biosafety testing facilities for adventitious agent screening of raw materials, cell lines and unprocessed bulk along with our extensive viral clearance capabilities is available to provide our clients with a single-source biosafety testing service offering.
Biosafety Testing
High quality, in-house and EMA, ISO (CNAS) and CMA certified biosafety testing facilities for adventitious agent screening of raw materials, cell lines and unprocessed bulk along with our extensive viral clearance capabilities is available to provide our clients with a single-source biosafety testing service offering.
Learn more
-
Analytical Testing
$We offer an extensive array of assay development and analytical testing services, including bioassay development and forensic investigation analysis, along with other key characterization and IND and BLA-enabling studies throughout the various phases of drug development – all tailored for your unique product and project needs.
Analytical Testing
We offer an extensive array of assay development and analytical testing services, including bioassay development and forensic investigation analysis, along with other key characterization and IND and BLA-enabling studies throughout the various phases of drug development – all tailored for your unique product and project needs.
Learn more
-
Bioassay Method Development Services
-
Product Characterization Service
-
Routine Analytical Testing Services
-
Centers of Excellence (CoE)
$Our CoEs support projects with specialized testing throughout the product lifecycle, expediting project timelines and ensuring analytical readiness for commercialization.
Centers of Excellence (CoE)
Our CoEs support projects with specialized testing throughout the product lifecycle, expediting project timelines and ensuring analytical readiness for commercialization.
Learn more
-
Global Quality Control (QC)
$Regulatory compliant, in-house, QC labs support all clinical and commercial GMP sites pre- and post-production, ensuring top-quality testing for products and oversight of other critical functions (e.g., environmental monitoring, cleaning validations, instrument life-cycle and sample/retain management and audits).
Global Quality Control (QC)
Regulatory compliant, in-house, QC labs support all clinical and commercial GMP sites pre- and post-production, ensuring top-quality testing for products and oversight of other critical functions (e.g., environmental monitoring, cleaning validations, instrument life-cycle and sample/retain management and audits).
Learn more
-
Quality
-
Quality & Regulatory
$We provide world-class quality systems, harmonized across our global manufacturing sites and approved by multiple global regulatory agencies, including the U.S. FDA, EMA, NMPA, PMDA, MFDS, HSA, ANVISA and Health Canada for the production and testing of a wide array of biologics.
-
Global Compliance
$Oversees global quality system and audit, IT quality, internal compliance, and risk analytics functions. This team embeds quality and compliance across the entire organization to ensure the products we manufacture are of the highest efficacy and safety standards and in line with your expectations.
Global Compliance
Oversees global quality system and audit, IT quality, internal compliance, and risk analytics functions. This team embeds quality and compliance across the entire organization to ensure the products we manufacture are of the highest efficacy and safety standards and in line with your expectations.
Learn more
-
Quality Assurance
$Global systems meet regulatory standards, ingrained commitment to quality from CEO to employees, harmonized QA across worldwide sites for biologics and vaccines production.
Quality Assurance
Global systems meet regulatory standards, ingrained commitment to quality from CEO to employees, harmonized QA across worldwide sites for biologics and vaccines production.
Learn more
-
Quality Control
$Regulatory compliant, in-house, QC labs support all clinical and commercial GMP sites pre- and post-production, ensuring top-quality testing for products and oversight of other critical functions (e.g., environmental monitoring, cleaning validations, instrument life-cycle and sample/retain management and audits).
Quality Control
Regulatory compliant, in-house, QC labs support all clinical and commercial GMP sites pre- and post-production, ensuring top-quality testing for products and oversight of other critical functions (e.g., environmental monitoring, cleaning validations, instrument life-cycle and sample/retain management and audits).
Learn more
-
Regulatory Affairs
$Our experienced regulatory affairs team supports our client’s CMC dossier, drug filing and registration needs. Since 2015 this team has supported 550+ INDs, CTAs, BLAs, MAAs, NDAs and EUAs, and written 200+ Module 3 CMC packages on behalf of our global clients.
Regulatory Affairs
Our experienced regulatory affairs team supports our client’s CMC dossier, drug filing and registration needs. Since 2015 this team has supported 550+ INDs, CTAs, BLAs, MAAs, NDAs and EUAs, and written 200+ Module 3 CMC packages on behalf of our global clients.
Learn more
-
Featured Platforms
-
Integrated Platforms
$Comprehensive, high-quality, end-to-end solutions driving efficiency, decreasing time to clinic and reducing project risks from concept to commercialization.
-
Target to Lead
$Providing expertise, highly efficient tailored solutions, state-of-the-art technologies and world-class facilities for the engineering, generation, and optimization of antibodies and other biologics from target identification to final lead selection.
Target to Lead
Providing expertise, highly efficient tailored solutions, state-of-the-art technologies and world-class facilities for the engineering, generation, and optimization of antibodies and other biologics from target identification to final lead selection.
Learn more
-
DNA to IND
$Providing industry-leading 10-month (or less) DNA to IND timeline for biologics by leveraging our single-source, high-quality, and well-vetted development platform across all CMC activities.
DNA to IND
Providing industry-leading 10-month (or less) DNA to IND timeline for biologics by leveraging our single-source, high-quality, and well-vetted development platform across all CMC activities.
Learn more
-
IND to BLA
$Streamlined late-phase development and manufacturing services, ensuring BLA filing in 15 months or less, with global commercialization support through our highly-vetted development platforms.
IND to BLA
Streamlined late-phase development and manufacturing services, ensuring BLA filing in 15 months or less, with global commercialization support through our highly-vetted development platforms.
Learn more
-
Discovery Technologies
$A full spectrum of discovery services and technologies for the engineering, generation, characterization, optimization and selection of high-potency novel antibody therapeutics.
-
Development Technologies
$Cutting-edge bioprocessing platforms and technologies designed to enable high-quality biologics to enter clinical trials faster, more efficiently and more cost-effectively.
-
Ultra-Intensified Fed-batch platform – WuXiUI™
$Ultra-intensified fed-batch bioprocessing platform utilizes an intermittent perfusion approach to achieve 3-6-fold higher productivity and 60 – 80% reduction in manufacturing cost of goods compared to traditional fed-batch processes.
Ultra-Intensified Fed-batch platform - WuXiUI™
Ultra-intensified fed-batch bioprocessing platform utilizes an intermittent perfusion approach to achieve 3-6-fold higher productivity and 60 – 80% reduction in manufacturing cost of goods compared to traditional fed-batch processes.
Learn more
-
Cell Line Development – WuXia™
$Proven, high-yielding (up to 11 g/L) and high-quality cell line development platform, accepted by regulatory agencies worldwide.
Cell Line Development - WuXia™
Proven, high-yielding (up to 11 g/L) and high-quality cell line development platform, accepted by regulatory agencies worldwide.
Learn more
-
Continuous Bioprocessing – WuXiUP™
$This ultra-high productivity continuous bioprocessing platform, achieves 5-15X greater productivity, delivering high-yield, quality drug products with flexibility and cost-effectiveness through intensified perfusion culture, continuous harvest and optional downstream continuous product capture step.
Continuous Bioprocessing - WuXiUP™
This ultra-high productivity continuous bioprocessing platform, achieves 5-15X greater productivity, delivering high-yield, quality drug products with flexibility and cost-effectiveness through intensified perfusion culture, continuous harvest and optional downstream continuous product capture step.
Learn more
-
ADC Development Platform – WuXiDAR4™
$Our drug-to-antibody ratio and enrichment technology greatly enhances DAR4 (four payload molecules per mAb) percentage in the final ADC product and improves conjugation efficiency.
ADC Development Platform - WuXiDAR4™
Our drug-to-antibody ratio and enrichment technology greatly enhances DAR4 (four payload molecules per mAb) percentage in the final ADC product and improves conjugation efficiency.
Learn more
-
High Concentration & HTP DP Platform – WuXiHigh™
$Advanced high throughput formulation platform for development of high concentration biologics drug products using distinctive viscosity reducers and synergistic excipient combinations to enhance formulation stability and reduce viscosity.
High Concentration & HTP DP Platform - WuXiHigh™
Advanced high throughput formulation platform for development of high concentration biologics drug products using distinctive viscosity reducers and synergistic excipient combinations to enhance formulation stability and reduce viscosity.
Learn more
-
Monitoring and Predictive Control – PatroLab
$Real-time monitoring, predictive modeling, and automated process control synthesized into one digital platform.
Monitoring and Predictive Control - PatroLab
Real-time monitoring, predictive modeling, and automated process control synthesized into one digital platform.
Learn more
-
Manufacturing Technologies
$Advanced biomanufacturing platforms empower our global healthcare partners to deliver biologics to the clinic and on to the market for the benefit of patients worldwide.
-
Single-Use Bioreactors
$We operate several of the world’s largest single-use bioreactor facilities for biologics manufacturing, leveraging the risk reduction, flexibility, cost-effectiveness, and eco-friendliness offered by these systems.
Single-Use Bioreactors
We operate several of the world’s largest single-use bioreactor facilities for biologics manufacturing, leveraging the risk reduction, flexibility, cost-effectiveness, and eco-friendliness offered by these systems.
Learn more
-
Scale-Out Biomanufacturing
$Helping to pioneer this biomanufacturing strategy for higher volume production, we can help you reduce risk and increase manufacturing flexibility across the entire product lifecycle by using multiple, same-scale bioreactors to meet clinical and market demand.
Scale-Out Biomanufacturing
Helping to pioneer this biomanufacturing strategy for higher volume production, we can help you reduce risk and increase manufacturing flexibility across the entire product lifecycle by using multiple, same-scale bioreactors to meet clinical and market demand.
Learn more
-
Robotic Aseptic Filling
$Reducing manufacturing risk through the use of this fully programmable, robotic, gloveless, isolator-based technology for advanced aseptic drug product fill processing. These systems provide extensive flexibility to support complex fills across a wide range of biologics and container closure systems.
Robotic Aseptic Filling
Reducing manufacturing risk through the use of this fully programmable, robotic, gloveless, isolator-based technology for advanced aseptic drug product fill processing. These systems provide extensive flexibility to support complex fills across a wide range of biologics and container closure systems.
Learn more
-
Continuous Manufacturing Process
$Combining intensified perfusion culture (IPC) and continuous direct product capture (CDPC), and advanced equipment for increased productivity and cost reduction.
Continuous Manufacturing Process
Combining intensified perfusion culture (IPC) and continuous direct product capture (CDPC), and advanced equipment for increased productivity and cost reduction.
Learn more
-
Animal Health Technologies
$One-stop solution for superior animal health outcomes.
-
Sustainability
-
Careers
-
Investors
-
News & Resources
-
Contact Us
-
中文 / CN
-
Deutsch / DE
-
日本語 / JP
-
한글 / KR
Press Releases
Press Releases
2026
WuXi Biologics at Festival of Biologics Basel 2026: Turning Scientific Complexity into Commercial Certainty
News
October 19, 2026

Share



WuXi Biologics at Festival of Biologics Basel 2026: Turning Scientific Complexity into Commercial Certainty
More than 3,000 industry professionals gathered at Festival of Biologics Basel 2026 to exchange insights on the future of biologics. Extending this industry conversation, WuXi Biologics hosted its 3rd annual Basel CRDMO+ Day, convening more than 100 biotechnology and pharmaceutical leaders and experts to discuss a common challenge: how to develop, manufacture and deliver increasingly complex biologics faster, more reliably and with greater certainty.
As biologics pipelines expand beyond conventional monoclonal antibodies into bispecific antibodies, ADCs and other advanced modalities, innovators face a broader set of interconnected decisions across molecule design, manufacturability, scale-up and commercialization. Addressing these decisions early can help shorten timelines, reduce risk, and improve execution across the product lifecycle.
Scaling Complex Biologics with Greater Speed and Predictability
The biologics industry is entering a new phase of complexity. Bispecific antibodies, ADCs, and other advanced modalities now represent a growing share of innovation pipelines.
Supporting innovation at scale requires both capacity and execution. WuXi Biologics will expand annual capacity for approximately 300 IND programs and 20 BLA programs by 2027, supported by a portfolio of 1,064 integrated projects, including 399 first-in-class programs, 732 global IND clearances, and more than 90 market authorizations.
The shift toward complex molecules is already visible within this portfolio. Of the 169 projects added during the first half of 2026, 71% were bispecific antibodies or ADCs. More than two-thirds of these new programs originated from the United States and Europe, underscoring growing demand for increasingly sophisticated biologics.
Video Player
https://cdn.wuxibiologics.com/en/wp-content/uploads/2026/09/20260902090240378.mp4
00:00
00:00
03:43
For innovators, the value of platform innovation lies in making early development faster and more predictable. The WuXia™ TrueSite Targeted Integration platform, has been adopted in 70+ projects, delivers average clone titers of 8 g/L, near-100% clone stability and significantly improved pool-to-clone consistency. These improvements can substantially reduce downstream development risk while accelerating progression toward IND.
Speed has emerged as a critical strategic lever in biologics development. WuXi Biologics introduced its clone-derived six-month DNA-to-IND solution six years ago. Using final production clones rather than pool-derived materials, reducing future comparability risks while significantly shortening development timelines. Since its launch, the platform has been applied across 66 accelerated programs, with 6 assets advancing into late-stage and commercial manufacturing.
Identifying the Right Platform for the Right Molecule
As molecule diversity increases, selecting the right pathway and manufacturing platform has become a strategic advantage.
Rather than applying a single development model across all molecules, developers increasingly require fit-for-purpose platforms that address specific biological, manufacturability, and scale-up challenges.
To support this evolution, WuXi Biologics has expanded beyond traditional mammalian expression systems into microbial and HEK293 development platforms supporting enzymes, cytokines, antibody fragments, nanobodies, recombinant proteins, and other emerging modalities.
The microbial platform provides a strong example of this expansion. Microbial-derived biologics now represent a significant and growing portion of the biologics landscape. WuXi Biologics has accumulated experience from more than 3,000 fermentation runs across more than 140 molecules, with commercial scale-up experience reaching 15,000 liters.
Its knowledge-driven development approach has enabled:
- 30%-50% faster development timelines
- More than 95% first-time scale-up success rates
- Sequence-to-GMP drug substance release in approximately 9.5 months
- Technology transfer to BLA timelines reduced from approximately 30 months to as little as 18 months
The platform also demonstrates how process innovation drives stronger commercial economics. Across multiple programs, process optimization, scale-up strategies and raw-material improvements have generated total cost reductions of approximately 40%-50%. For developers preparing to scale, these improvements can strengthen cost competitiveness while reducing the operational burden of commercial manufacturing.
Designing for Treatment Convenience and Efficiency
For many biologics, competitive advantage is increasingly determined not only by molecular performance, but also by how therapies are designed and delivered to better meet patient needs and improve treatment convenience.
As healthcare systems push toward greater convenience and efficiency, high-concentration formulations, subcutaneous delivery and drug-device combination products are becoming critical strategic considerations much earlier in development.
WuXi Biologics has now supported:
- More than 500 formulation and drug product processes
- More than 180 high-concentration biologics programs
- More than 130 programs reaching concentrations up to 240 mg/mL
- More than 30 syringe and combination-device programs
The company’s WuXiHigh™ 2.0 platform has expanded formulation screening from 8 to 24 formulations in parallel while delivering viscosity reductions of up to 90%. These capabilities support concentration that would previously have been considered impractical for routine development and manufacturing.
Innovation continues beyond conventional high-concentration formulations. New ultra-high-concentration approaches are targeting protein concentrations up to 500 mg/mL, opening opportunities for next-generation subcutaneous and intramuscular delivery.
Hyaluronidase-enabled co-formulation has emerged as another rapidly growing area, supported by more than 30 projects. These approaches can significantly reduce administration time while improving patient convenience and product competitiveness.
As biologics grow more complex and patient needs increasingly shape product design, drug product development is becoming a strategic differentiator rather than a downstream activity.
Turning Development Know-How into Commercial Success
Scientific innovation creates value only when it can be translated into consistent commercial supply.
To help clients plan for regional supply and future demand, WuXi Biologics operates a global manufacturing network exceeding 600,000 liters of planned bioreactor capacity across Ireland, Germany, Singapore, the United States, and China. Approximately half of this capacity is located outside China, supporting a resilient global supply strategy.
The company’s commercial track record includes:
- A 100% PPQ campaign success rate
- More than 2,600 drug substance batches delivered with a 98.7% success rate
- More than 2,670 drug product batches delivered with a 99.6% success rate
As biologics programs advance toward commercialization, technology transfer is becoming a critical bridge between development speed and manufacturing readiness. WuXi Biologics has completed more than 220 transfer-in projects involving more than 10 host cell lines and multiple molecule classes. Accelerated programs have achieved GMP drug substance vial thaw in less than three months, with more than 10 programs completed in under two months.
WuXi Biologics’ dual-sourcing strategy gives clients greater agility and resilience in global supply, providing a proven pathway to expand commercial production across sites with greater confidence. Several commercial products have successfully launched first in China and subsequently in Ireland, with PPQ completion at the second site occurring as little as one year while maintaining comparability and, in some cases, upgrading process performance and reducing cost.
Commercial process optimization remains a significant value driver. Through multiple commercial programs, manufacturing innovations have delivered:
- Up to 450% titer increases
- Up to 80% cost-of-goods reductions
- Up to 200% productivity increases through media and process improvements
The impact extends beyond manufacturing. Programs supported by WuXi Biologics have been associated with 140 acquisitions and 42 client IPOs, demonstrating how reliable execution can help clients advance critical assets and create value at pivotal stages of company growth.
Building Predictability Through Digitalization
As biologics become more complex, the ability to translate data into actionable insights is becoming critical to reducing uncertainty and improving predictability.
WuXi Biologics is integrating digital capabilities across development, manufacturing, quality and customer collaboration to improve visibility, accelerate decision-making and strengthen execution.
Digital platforms support technology transfer, manufacturing planning, deviation investigation, process monitoring and customer engagement through a connected data environment. This includes PatroLab™, a digital manufacturing platform designed to increase process visibility, reduce risk, improve scale-up consistency and strengthen commercial robustness. Rather than reacting to variability after it occurs, the platform helps teams identify process drift earlier and convert manufacturing variability into more predictable commercial performance.
This transition toward a digital-native CRDMO aims to improve execution by combining scientific expertise, manufacturing knowledge and connected data to drive more predictable and efficient execution. Ultimately, the goal is greater visibility, earlier risk identification and increased certainty across the product lifecycle.
An Integrated Model for Biologics Success
The message from WuXi Biologics CRDMO+ Day Basel 2026 was clear.
As biologics become more complex, companies need more than access to individual technologies, manufacturing facilities or isolated service providers. They need an integrated CRDMO model that connects discovery, CMC, manufacturing, drug product development, digitalization and commercial supply within a single framework, reducing handoffs and enabling faster, better-informed decisions across the product lifecycle.
The next frontier of biologics innovation is not only about discovering more advanced molecules, but about bringing them to patients with greater speed, resilience and certainty. For innovators, an integrated partner can bridge the gap between scientific complexity and commercial success, turning complexity into a more predictable path from molecules to market.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics — from concept to commercialization — for the benefit of patients worldwide*.
With over 14,000 employees in China, the United States, Ireland, Germany, and Singapore, including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence, WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients’ needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of June 30, 2026, WuXi Biologics is supporting 1064 integrated client projects, including 78 in Phase III and 28 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain.